Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term chemotherapy. Found 241 abstracts

no pagination
Dominici L, Najita J, Hughes M, Niland J, Marcom P, Wong YN, Carter B, Javid S, Edge S, Burstein H, Golshan M. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Research and Treatment. 2011 Sep;129(2):459-65.   PMCID: PMC3382105
Elkin EB, Klem ML, Gonzales AM, Ishill NM, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Constine LS, Myrehaug S, Yahalom J. Characteristics and Outcomes of Breast Cancer in Women With and Without a History of Radiation for Hodgkin's Lymphoma: A Multi-Institutional, Matched Cohort Study. Journal of Clinical Oncology. 2011 Jun;29(18):2466-73.   PMCID: PMC3138631[Available on 2012/6/20]
Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WN. Occult Primary Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2011 Dec;9(12):1358-95.   PMCID: not NIH funded
Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Research and Treatment. 2011 Sep;129(2):451-8.   PMCID: *
Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Annals of Oncology. 2011 Apr;22(4):939-46.   PMCID: not NIH funded
Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research. 2011 Jun;13(3):R67.   PMCID: PMC3218956
Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, Stany MP, Rose GS, Markman M, Ozols RF, Armstrong DK, Maxwell GL. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study. Gynecologic Oncology. 2011 Sep;122(3):521-6.   PMCID: *
Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. International Journal of Clinical Oncology. 2011 Oct;16(5):596-600.   PMCID: *
Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology. 2011 Sep;68(3):703-12.   PMCID: not NIH funded
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC. Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network. 2011 Oct;9(10):1086-113.   PMCID: not NIH funded
Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. Journal of Clinical Oncology. 2011 Jul;29(19):2660-6.   PMCID: not NIH funded
Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU international. 2011 Jul;108(2B):E84-E90.   PMCID: PMC3116980
McHugh JA, Cullison S, Apuzzio J, Block JM, Cohen C, Leong SL, London WT, McNellis RJ, Neubauer RL, Perrillo R, Squires R, Tarrant D, McMahon BJ. Chronic hepatitis B infection: A workshop consensus statement and algorithm. Journal of Family Practice. 2011 Sep;60(9):E1-8.   PMCID: not NIH funded
Mego M, De Giorgi U, Dawood S, Wang XM, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. International journal of cancer. 2011 Jul;129(2):417-23.   PMCID: not NIH funded
Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang XM, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A, Woodward WA. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)CD24(lo) cancer stem cell phenotype. European Journal of Cancer. 2011 Jul;47(10):1527-36.   PMCID: PMC3116032
Salama JK, Saba N, Quon H, Garg MK, Lawson J, McDonald MW, Ridge JA, Smith RV, Yeung AR, Yom SS, Beitler JJ, Expert Panel Radiation O. ACR appropriateness criteria (R) adjuvant therapy for resected squamous cell carcinoma of the head and neck. Oral Oncology. 2011 Jul;47(7):554-9.   PMCID: not NIH funded
Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, MacDonald JS, Willett CG. THE INFLUENCE OF TOTAL NODES EXAMINED, NUMBER OF POSITIVE NODES, AND LYMPH NODE RATIO ON SURVIVAL AFTER SURGICAL RESECTION AND ADJUVANT CHEMORADIATION FOR PANCREATIC CANCER: A SECONDARY ANALYSIS OF RTOG 9704. International Journal of Radiation Oncology Biology Physics. 2011 Dec;81(5):1328-35.   PMCID: PMC3038247
Swaby RF, Cristofanilli M. Circulating tumor cells in breast cancer: A tool whose time has come of age. BMC Medicine. 2011 Apr;9:43.   PMCID: PMC3107794
Wong YN, Ottesen RA, Hughes ME, Niland JC, Theriault R, Edge SB, Blayney D, Weeks JC. Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?. The oncologist. 2011 Jan;16(5):559-65.   PMCID: PMC3228199
Zhang H, Kouadio A, Cartledge D, Godwin AK. Role of gamma-synuclein in microtubule regulation. Experimental Cell Research. 2011 Jun;317(10):1330-9.   PMCID: *
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term chemotherapy

chemotherapy survival expression therapy progression radiotherapy trial peripheral-blood carcinoma positron-emission-tomography system HER2 her2 prediction cancer bevacizumab NCCN Clinical Practice Guidelines resection metastatic breast-cancer NCCN Guidelines resistance management phase-ii prognostic-factors 1993 lisle l-archives of internal medicine-v153-p746 recommendations therapeutic strategy squamous-cell carcinoma occult primary micrometastases Nodal ratio locally advanced head surgical long-term survival phase-iii randomized trial 2nd cancer colony-stimulating factor chain-reaction assay poorly Triple-receptor prospective aggressive surgery daily thoracic radiotherapy Circulating tumor cell Microscopic residual risk unknown primary site 2006 i ds-v24-p2396 induced emesis myeloma esophageal cancer 2008 iorean eg-v26-p2008 united-states gene Cancer Gamma-synuclein-Drug resistance-Paclitaxel-Microtubule node-positive head palonosetron cisplatin plus tubulin plus neuroendocrine tumors radical cystectomy forthcoming 7th edition solid tumors chemotherapy-induced nausea small Metastatic breast cancer intraperitoneal cisplatin Mastectomy phase-iii trial curative resection reconstruction experience metabolism multicenter randomized-trial carcinoma of unknown primary regression aneusomy carboplatin yield Sunitinib oral tongue Antiangiogenesis ductal adenocarcinoma virus infection Chemoradiotherapy dexamethasone gene amplification metastatic consensus conference pancreaticoduodenectomy rapamycin association childhood beta blood vegf surgery Chemotherapy 5-ht3 receptor cancer-research-network moderately emetogenic glioblastoma NSCLC prognostic factors identification site phase-ii trial amplification cell mortality chemoradiotherapy head and neck quality-of-life standard ondansetron postoperative radiation-therapy mammalian target Polysomy cell lung-cancer bladder cancer mouse model combination-chemotherapy regimens growth-factor in-vitro Post-operative radiotherapy head and neck Stage IV breast cancer 2009 doloff da-j natl compr canc s2-v7-p1 Breast neoplasm epithelial-mesenchymal transition network growth-factor receptor prognostic factor circulating tumor cells-breast cancer cooperative-oncology-group Lymph node Radiation therapy lamivudine sorafenib age ret protooncogene mutations Head and neck cancer high-dose melphalan Prognosis Solid tumor paclitaxel met Survival Phase I neoadjuvant differentiated adenocarcinoma
Last updated on Thursday, June 04, 2020